Sunitinib malate

Red

Brand Name(s):Sutent

Indication:Advanced/Metastatic renal cell carcinoma.

Rationale:1,2,3,8

Considered:Sep-06

Review Date:Sep-21

Comments:
Cases of osteonecrosis of the jaw have been reported in cancer patients in association with sunitinib (Sutent) treatment, the majority of whom had received prior or concomitant treatment with i.v. bisphosphonates.

Sutent treatment may be an additional risk factor for the development of osteonecrosis of the jaw.

This potential risk should be particularly considered when Sutent and bisphosphonates are administered simultaneously or sequentially.

Dental examination and appropriate preventitive dentistry should be considered prior to treatment with Sutent. In patients who have previously received or are receiving i.v. bisphosphonates invasive dental procedures should be avoided, if possible.

Osteonecrosis of the jaw in cancer patients in association with sunitinib (Sutent) and concomitant or previous use of bisphosphonates MHRA November 2010

Risks of incorrect dosing of oral anti-cancer medicines – NPSA January 2008